Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial

Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial

Show other versions (1)

<h4>Background</h4> STAMPEDE has previously reported that radiotherapy (RT) to the prostate improved overall survival (OS) for patients with newly diagnosed prostate cancer with low metastatic burden, but not those with high-burden disease. In this final analysis, we report long-term fin...

Full description

Bibliographic Details
Main Authors: Chris C. Parker, Nicholas D. James, Christopher D. Brawley, Noel W. Clarke, Adnan Ali, Claire L. Amos, Gerhardt Attard, Simon Chowdhury, Adrian Cook, William Cross, David P. Dearnaley, Hassan Douis, Duncan C. Gilbert, Clare Gilson, Silke Gillessen, Alex Hoyle, Rob J. Jones, Ruth E. Langley, Zafar I. Malik, Malcolm D. Mason, David Matheson, Robin Millman, Mary Rauchenberger, Hannah Rush, J Martin Russell, Hannah Sweeney, Amit Bahl, Alison Birtle, Lisa Capaldi, Omar Din, Daniel Ford, Joanna Gale, Ann Henry, Peter Hoskin, Mohammed Kagzi, Anna Lydon, Joe M. O’Sullivan, Sangeeta A. Paisey, Omi Parikh, Delia Pudney, Vijay Ramani, Peter Robson, Narayanan Nair Srihari, Jacob Tanguay, Mahesh K. B. Parmar, Matthew R. Sydes, for the STAMPEDE Trial Collaborative Group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-06-01
Series:PLoS Medicine
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9173627/?tool=EBI

Similar Items

Similar Items